Abstract
Cardiac metabolism refers to a complex system of interconnected chemical reactions. In broad terms, metabolism provides the energy for contraction and the materials for the heart’s structure and function. A defining feature of metabolism is the flux of chemical compounds that can be traced by physical methods, including radioactive decay of tracers or magnetic resonance spectroscopy. Metabolic activity is a dynamic process found only in living cells and tissues. In addition to the dynamic nature of metabolic activity, intermediary metabolites also control cell function, either as regulators of enzyme activity or as posttranslational modifiers of protein function and transcriptional activity. An important recent development in the field of nuclear cardiology is the concept that metabolic remodeling of the heart precedes, triggers, and sustains structural and functional remodeling, and that metabolism is inextricably linked to both physiology and molecular biology of the heart. This concept offers unprecedented opportunities for metabolic imaging.
Access provided by Autonomous University of Puebla. Download chapter PDF
Similar content being viewed by others
Keywords
- Imaging of energy substrate metabolism
- Metabolic regulation
- Metabolic remodeling of cardiac structure and function
Introduction
Cardiac metabolism refers to a complex system of interconnected chemical reactions. In broad terms, metabolism provides the energy for contraction and the materials for the heart’s structure and function. A defining feature of metabolism is the flux of chemical compounds that can be traced by physical methods, including radioactive decay of tracers or magnetic resonance (MR) spectroscopy. These methods are readily applied both in vivo and ex vivo for the assessment of cardiac metabolic activity [1]. Metabolic activity, in turn, is a dynamic process found only in living cells and tissues. In addition to this dynamic nature of metabolic activity, intermediary metabolites also control cell function, either as regulators of enzyme activity or as posttranslational modifiers of protein function and transcriptional activity [2, 3].
An important recent development in the field of nuclear cardiology is the concept that metabolic remodeling of the heart precedes, triggers, and sustains structural and functional remodeling, and that metabolism is inextricably linked to both physiology and molecular biology of the heart. This concept offers unprecedented opportunities for metabolic imaging [4].
The pathways of myocardial energy substrate metabolism converge on the energy-rich phosphate bonds of ATP (Fig. 9.1) . ATP is largely used to maintain myocardial contraction and to regulate the membrane pumps and movements of ions in and out of the cell. For a given physiologic environment, the heart consumes the most efficient metabolic fuel for its function [6]. In the normally oxygenated heart, fatty acids account for the majority of ATP production; glucose makes only a small contribution in providing energy, unless there is an insulin surge. During an acute increase in work load (for example, inotropic stimulation), the heart immediately mobilizes its metabolic reserve contained in glycogen (transient increase in glycogen oxidation) and meets the needs for additional energy from the oxidation of carbohydrate substrates (glucose and lactate). When the oxygen supply is decreased, the heart protects itself from an oxygen-deficient state by switching its energy source to glycolysis, downregulating mitochondrial oxidative metabolism and reducing contractile function. Thus, the tight coupling between metabolism and contractile function in the heart offers a unique opportunity to assess cardiac performance in coronary flow, myocardial perfusion, oxygen delivery, metabolism, and contraction.
The advantages of imaging cardiac metabolism rest in the observer’s ability to monitor and trace chemical processes in the heart by noninvasive methods. In reality, cardiac metabolism consists of a complex and highly regulated biological network of intracellular reactions that is well characterized at the biochemical level [1].
No doubt, the interrelationship between mechanical function, myocardial perfusion, and metabolic and energy-consuming processes within the heart is complex. Existing knowledge can be reduced to a few principles: A metabolic switch from fatty acids to glucose seems pivotal in preserving myocardial viability and likely represents the earliest adaptive response to myocardial ischemia. Perhaps the most dramatic clinical application for the metabolic switch from fatty acid utilization to glycolysis is in myocardial hibernation. Hibernating myocardium represents the dysfunctional but viable myocardium, most likely the result of extensive cellular reprogramming due to repetitive episodes of chronic ischemia. This reprogramming of myocytes occurs at multiple levels. Although the true mechanism for viability remodeling in hibernation is likely to be very complex, it is thought to be related, in part, to the increased glycogen content and myocardial ATP levels in such cells, simulating the fetal heart. Because glucose transport and phosphorylation is readily traced by the uptake and retention of 18F-fluoro,2-deoxy-D-glucose (FDG), hibernating myocardium is readily detected by enhanced glucose uptake in the same regions by external detectors, such as positron emission tomography (PET).
Recent clinical studies have also shown the potential utility of metabolic adaptation in the emergency department as well as for detection of coronary artery disease in the form of “ischemic memory.” Ischemic memory represents prolonged but reversible metabolic recovery after transient myocardial ischemia, also known as “metabolic stunning.” At the cellular level, it is the result of extensive transcriptional, translational, and post-translational metabolic changes.
Other disease entities in which metabolic imaging by nuclear techniques can play an important role include diabetic heart disease, the identification of microvascular disease and subendocardial ischemia in symptomatic patients with nonobstructive coronary artery disease, and left ventricular remodeling in hypertrophy and congestive heart failure. The understanding of this kind of left ventricular remodeling has increased dramatically in recent years. Emerging evidence suggests a role for altered metabolism in the progression of both left ventricular hypertrophy and remodeling. Some of the clinical evidence includes a variable prognosis in patients with similar left ventricular mass in hypertrophy; a loss of metabolic flexibility that may portend worse prognosis in patients with heart failure; and the development of modulators for medical treatment in heart failure, such as fatty acid oxidation inhibitors (e.g., ranolazine) and insulin sensitizers.
Metabolic adaptation serves as a mechanism of cell survival in response to an altered physiological state and represents one of the earliest responses to myocardial ischemia, left ventricular remodeling, and diabetic and uremic heart disease. Recognizing key intracellular signals that link energy substrate metabolism with gene expression may allow the discovery of more specific molecular targets for the imaging, diagnosis, and treatment of cardiovascular disease.
Evolution of Knowledge of Cardiac Metabolism
The acquisition of knowledge of cardiac metabolism is highlighted by a number of early milestones:
-
1854: Hermann von Helmholtz discovers the first law of thermodynamics, introducing the concept that energy bound up in foodstuffs is liberated and transferred to physical work.
-
1857: Louis Pasteur discovers that fermentation occurs in living microorganisms and can be turned off by oxygen. When the oxygen supply is diminished, the rate of glucose utilization was increased and paralleled by an increase in lactate release. This stimulation of glycolysis by hypoxia and the corollary inhibition of anaerobic glycolysis by oxidative metabolism is termed the Pasteur effect .
-
1895: Oscar Langendorff demonstrates that the mammalian heart receives oxygen and nutrients through coronary circulation.
-
Early 1900s: Ernest Starling discovers that in normally oxygenated hearts, glucose contributes only a small amount to the fuel of the heart, in the absence of insulin.
-
1904: Ludwig Winterstein discovers the oxygen dependency of the contracting mammalian heart.
-
1904: Franz Knoop discovers β-oxidation of fatty acids, the metabolic oxidation at the β-carbon atom of a long-chain fatty acid by successive cycles of reactions, during each of which the fatty acid is shortened by a two-carbon-atom fragment removed as acetyl-coenzyme A.
-
1924: Otto Warburg describes the nature and function of mitochondrial respiratory enzymes. He discovers that a fundamental difference between normal and cancerous cells is the ratio of glycolysis to respiration; this observation is known as the Warburg effect . The concept that cancer cells switch from oxidative metabolism to glycolysis has become widely accepted and is the basis of 18F-FDG positron emission tomography (PET) imaging today.
-
1930s: C. Lovatt Evans et al. find that lactate can be readily taken up and oxidized as a fuel in the normally oxygenated heart.
-
1937: Hans A. Krebs discovers the major metabolic cycle—known as the Krebs cycle , or the citric acid cycle —which represents the second of the three steps that convert fatty acids, glucose, and other fuels in the body into energy in the form of adenosine triphosphate (ATP).
-
1937: Fritz A. Lipmann discovers the importance of ATP as the main energy carrier in cells; he later shared the 1953 Nobel Prize for Physiology or Medicine with Hans Krebs for his discovery of coenzyme A (CoA), a crucial link between glycolysis, the first stage in the process, and the Krebs cycle, and its importance for intermediary metabolism.
-
1950s: Richard J. Bing, using coronary sinus cannulation and precise coronary artery flow measurements in the human heart, discovers the concept of the heart as a metabolic omnivore.
-
1960s: Philip J. Randle discovers that fatty acids suppress glucose oxidation by inhibiting pyruvate dehydrogenase in the isolated perfused heart.
-
1960s: Richard J. Bing introduces positron-emitting tracers for the measurement of blood flow.
Metabolic Radiotracers
By labeling various compounds of physiologic interest, valuable insights into biochemical pathways and tissue metabolism can be obtained in functional and dysfunctional myocardium (Table 9.1). Currently, the only PET myocardial metabolic radiotracer approved by the US Food and Drug Administration (FDA) and reimbursable by the Centers for Medicare & Medicaid Services is 18F-fluoro,2-deoxy-D-glucose (FDG), which is the current gold standard for evaluating glucose metabolism, and myocardial viability. FDG is a glucose analogue that competes with glucose for phosphorylation by hexokinase. Once phosphorylated, it is trapped inside the cell and can be neither further metabolized nor exported back out of the cell. To assess fatty acid utilization, earlier studies used the labeled substrate 11C-palmitate, which is a PET-radiolabeled straight-chain fatty acid. After its uptake into the cell and activation by binding to coenzyme A, 11C-palmitate undergoes β-oxidation, ultimately leading to the release of 11CO2. However, this technique requires a PET camera and an onsite cyclotron. As single-photon emission computed tomography (SPECT) cameras were already available to most nuclear cardiologists, the focus turned to the development of SPECT tracers for fatty acid oxidation. One of them is [123I]-β-methyl-p-iodophenyl-pentadecanoic acid (123I-BMIPP) , a substrate analogue that is rapidly taken up into the cardiomyocytes and shows prolonged retention due to limited catabolism. Both 123I-BMIPP and 11C-palmitate interrogate myocardial fatty acid metabolism in vivo. The uptake and clearance of 11C-palmitate from the myocyte occurs quite rapidly via β-oxidation, whereas the methyl chain in 123I-BMIPP results in metabolic trapping of the radiotracer in the myocyte. A PET-radiolabeled short-chain acid that is ideal for the in vivo assessment of myocardial oxidative metabolism is 11C-acetate.
Changes in fatty acid and glucose metabolism have been long-established parts of metabolic remodeling in various forms of heart disease, but much less is known about the alterations in amino acid metabolism and their impact on the onset and progression of cardiac disease. 11C-glutamate or 13N-glutamate are also useful for tracing the footprints of myocardial ischemia, and the uptake of 11C-methionine in infarcted areas during the acute phase after myocardial infarction is a useful tool in monitoring the remodeling of the heart after myocardial infarction.
Figures 9.2, 9.3, and 9.4 illustrate the metabolic pathways in the heart and the ways that radiotracers and tracer analogues can assess perfusion, substrate uptake, and other evidence of metabolic activity. The flux of energy is limited to a series of moiety-conserved cycles (Fig. 9.2).
Metabolic Signals in Normal and Diseased Heart: Opportunities for Molecular Imaging
A refined understanding of metabolic regulation may result in the early diagnosis and treatment of subclinical myocardial ischemia and heart failure, as metabolic changes and changes in gene expression are likely to precede contractile dysfunction and other functional remodeling of the stressed heart (Figs. 9.5, 9.6, 9.7, 9.8, 9.9, 9.10, 9.11, and 9.12).
Clinical Application of Myocardial Metabolism: PET and SPECT Techniques
PET Techniques: 11C-Palmitate
The principle of using a metabolic tracer for myocardial imaging is based on the concept that viable myocytes in hypoperfused and dysfunctional regions are metabolically active, whereas scarred or fibrotic tissue is metabolically inactive. Under fasting and aerobic conditions, long-chain fatty acids are the preferred fuel in the heart; they supply 65–70% of the energy for the working heart, and approximately 15–20% of the total energy supply comes from glucose. Thus, early studies have focused on using PET to characterize the myocardial kinetics of the long-chain fatty acid tracer 11C-palmitate. Uptake of 11C-palmitate by the heart is dependent on regional perfusion, diffusion across the sarcolemmal membrane, transporter protein, and acceptance in the cytosol by binding to coenzyme A (CoA). In normally perfused myocardium, the extraction fraction of 11C-palmitate is 40%. Transported across the sarcolemma by a transporter protein (CD36) of long-chain fatty acid, the myocyte fatty acids are bound to a binding protein. Metabolic activation of 11C-palmitate occurs through attachment to CoA. Depending on demand, about 80% of the extracted 11C-palmitate is activated for transport from the lipid pool into the mitochondria (via the carnitine shuttle) for breakdown by β-oxidation, which results in the generation of carbon dioxide that appears in the venous effluent of the coronary circulation in less than a minute after 11C-acyl-CoA transfers into the mitochondria (Fig. 9.13). Following is a summary of the PET technique:
-
Image acquisition starts at 15–20 mCi bolus injection of the tracer and continues 40–60 minutes.
-
Initial uptake and distribution in the myocardium is determined primarily by regional blood flow.
-
In the cytosol, 11C-palmitate is esterified to 11C-acyl-CoA , which is mediated by thiokinase, an energy-dependent reaction, resulting in trapping of the tracer in the myocardium.
-
Thereafter, 11C-acyl-CoA either enters the endogenous lipid pool as 11C glycerides and 11C phospholipids or moves via the carnitine shuttle to the mitochondria, where rapid degradation by β-oxidation results in the generation of carbon dioxide.
SPECT Technique: 123I-BMIPP
Alterations in myocardial fatty acid metabolism were first evaluated noninvasively in humans using 11C-palmitate, which requires an onsite cyclotron and a PET camera. Because most nuclear cardiology laboratories are equipped with SPECT cameras, investigators subsequently focused their attention on developing gamma-emitting fatty acid tracers. In contrast to palmitate, β-methyl-p-123I-iodophenyl-pentadecanoic acid (123I-BMIPP) is an iodine-labeled, methyl branched-chain fatty acid that is predominantly trapped in myocardial cells with limited catabolism. Uptake of BMIPP from the plasma into myocytes occurs via the CD36 transporter protein present on the sarcolemmal membrane (Fig. 9.14). Once in the cell, BMIPP will either back-diffuse to the plasma, accumulate in the lipid pool, or undergo limited α- and β-oxidation. Enzymatic conversion of BMIPP to BMIPP-CoA or triacylglycerol in the myocyte is ATP-dependent and is an irreversible step. Such conversion prevents the back-diffusion of BMIPP to the plasma and facilitates its cellular retention. The prolonged retention of BMIPP in the myocardium, combined with rapid clearance from the blood and diminished uptake in the liver and lung, results in excellent visualization and imaging of the myocardium by SPECT techniques. Thus, BMIPP provides a means of measuring myocardial fatty acid utilization in vivo. In the setting of myocardial ischemia, a reduction in ATP production secondary to diminished fatty acid metabolism is mirrored by decreased myocardial BMIPP uptake. BMIPP is approved for clinical use in Japan, but it has not yet received approval by the US FDA.
PET Technique: 11C-Acetate
11C-acetate is a short-chain fatty acid that is avidly extracted by the myocardium, with a first-pass extraction of 63% at blood flows of 1 mL/g/min. It is metabolized predominantly by mitochondrial oxidation. Once in the cytosol, the tracer is converted to acetyl-CoA by acetyl-CoA synthetase and is oxidized by the Krebs cycle in the mitochondria to 11C-carbon dioxide and water. Thus, the washout rate of 11C-acetate from myocardium is directly related to the oxidative metabolism. Given the close link between the Krebs cycle and oxidative phosphorylation, the myocardial turnover and clearance of 11C-acetate in the form of 11C-carbon dioxide may reflect overall oxidative metabolism and provide insight into the mitochondrial function of viable myocardium (Fig. 9.15). Alternative metabolic pathways of 11C-acetate include incorporation into amino acids, ketone bodies, and fatty acids by de novo synthesis or chain elongation, but these latter pathways are thought to be modest and unlikely to compromise estimation of regional myocardial oxygen consumption per minute.
PET and SPECT Techniques: 18F-FDG
18F-fluorodeoxyglucose (FDG) is a glucose analogue used to image myocardial glucose utilization with PET. Following an intravenous injection of 5–10 mCi FDG, FDG rapidly exchanges across the capillary and cellular membranes and is phosphorylated by hexokinase to FDG-6-phosphate. Once phosphorylated, FDG is not metabolized further in the glycolytic pathway, fructose-pentose shunt, or glycogen synthesis. Because the dephosphorylation rate of FDG is slow, essentially it becomes trapped in the myocardium, allowing adequate time to image regional glucose uptake by PET or SPECT. In the fasting and aerobic conditions, fatty acids are the preferred source of myocardial energy production, with glucose accounting for some 15–20% of the total energy supply. In the fed state, however, plasma insulin levels increase, glucose metabolism is stimulated, and tissue lipolysis is inhibited, resulting in reduced fatty acid delivery to the myocardium. The combined effects of insulin on these processes and the increased arterial glucose concentration associated with the fed state result in preferred glucose utilization by the myocardium. Myocardial FDG uptake is influenced by metabolic and hormonal milieu, workload, and blood flow.
The diagnostic quality of FDG imaging is critically dependent on a number of factors, such as hormonal milieu, substrate availability, and regional blood flow [20]. This becomes particularly evident when studying patients with clinical or subclinical diabetes. Most clinical studies are performed after 50–75 g glucose loading with oral dextrose approximately 1–2 hours before the FDG injection. Although 90% of FDG images are of adequate to excellent diagnostic quality in nondiabetic patients, the quality of FDG images after glucose loading is less certain in patients with clinical or subclinical diabetes mellitus. Because the increase in plasma insulin levels after glucose loading may be attenuated in patients with diabetes mellitus, tissue lipolysis is not inhibited and free fatty acid levels in the plasma remain high. The quality of FDG images in diabetics may be optimized by the use of standardization schemes:
-
Intravenous bolus of regular insulin
-
Most common and clinically feasible approach
-
Regular insulin is administered according to plasma glucose level and a predetermined sliding scale.
-
Plasma glucose level is assessed every 15 minutes, with the administration of additional boluses of insulin, if necessary.
-
FDG dose is injected once the plasma glucose level is below 140 mg/dL.
-
-
Hyperinsulinemic–euglycemic clamping
-
Insulin and glucose are infused simultaneously to achieve a stable plasma insulin level of 100–120 IU/L and a normal plasma glucose level.
-
The rate of glucose infusion (20% dextrose solution with potassium chloride) is adjusted intermittently based on measured glucose levels.
-
Although it provides excellent image quality, this technique is rather tedious and impractical for routine clinical studies.
-
-
Use of nicotinic acid derivative
-
Approximately 2 hours before the FDG dose injection, a single dose of nicotinic acid derivative is given orally, followed by glucose loading.
-
FDG image quality is comparable to that obtained after the clamping technique in the same patient population.
-
Metabolic Pathways and Patterns
The major metabolic pathways, as outlined in Fig. 9.16, offer opportunities to evaluate myocardial perfusion patterns with the use of PET and SPECT imaging and other techniques to find subclinical defects and determine whether myocardium remains viable after ischemia or infarction (Figs. 9.17, 9.18, 9.19, 9.20, 9.21, 9.22, 9.23, 9.24, 9.25, 9.26, and 9.27). An advantage of PET is that it can be safely performed in patients with an implanted cardiac defibrillator or renal insufficiency.
Similarly, the ability of PET to define a myocardial scar is of significant interest to electrophysiologists. A myocardial scar usually acts as the substrate for reentrant ventricular tachycardia (VT) and is present in the majority of patients with ischemic and nonischemic cardiomyopathy. During reentrant VT, an electrical wave front enters and traverses the myocardial scar via a network of electrically conducting channels. After exiting the scar, it depolarizes the rest of the ventricle and returns to the original entry site, repeating the cycle. This concept of entry sites, slowly conducting channels, and exit sites has been successfully validated in post–myocardial infarction patients during clinical electrophysiologic studies. The current “gold standard” of defining a myocardial scar is based on endocardial bipolar voltage recordings using a three-dimensional (3D) mapping system with a roving mapping catheter. Accordingly, regions with greater than 1.5 mV are classified as normal myocardium, 0.5–1.5 mV as abnormal myocardium, and less than 0.5 mV as scarred myocardium. Different from delayed–enhanced MRI and CT, which provide a morphologic substrate assessment, PET allows a metabolic characterization of the myocardial scar and its border zone. Current software developments are aimed at exporting this detailed 3D imaging information into the actual ablation procedure to provide anatomic guidance for patients with recurrent episodes of VT. In a recent study of patients undergoing VT ablation, a good correlation was found between PET-derived metabolic scar maps and endocardial voltage (r = 0.89, P <0.05). The scar size, location, and border zone accurately predicted high-resolution voltage map findings (r = 0.87, P <0.05). Moreover, PET/CT maps correctly predicted a nontransmural epicardial scar that was confirmed with epicardial mapping despite a normal endocardial map [37]. Figure 9.28 illustrates a fusion of CT and PET FDG images that could be used to guide VT ablation therapy.
Figures 9.29 and 9.30 demonstrate metabolic alterations in chronic kidney disease (CKD) and renal failure. The detection of early preclinical myocardial metabolic alterations in CKD can be limited. Although the distribution of FDG uptake may visually appear homogeneous throughout the left ventricular myocardium, absolute myocardial glucose utilization may be abnormal in these patients.
Finally, Fig. 9.31 demonstrates bone marrow cell homing, an example of the new fields of metabolomics and stem-cell imaging, which may offer new tools of metabolic imaging for the diagnosis and treatment of myocardial diseases.
References
Taegtmeyer H, Young ME, Lopaschuk GD, Abel ED, Brunengraber H, Darley-Usmar V, et al. American Heart Association Council on basic cardiovascular sciences. Assessing cardiac metabolism: a scientific statement from the American Heart Association. Circ Res. 2016;118:1659–701.
Kundu B, Zhong M, Sen S, Davogustto G, Keller S, Taegtmeyer H. Remodeling of glucose metabolism precedes pressure overload-induced left ventricular hypertrophy: review of a hypothesis. Cardiology. 2015;130:211–20.
Taegtmeyer H, Golfman L, Sharma S, Razeghi P, van Arsdall M. Linking gene expression to function: metabolic flexibility in the normal and diseased heart. Ann N Y Acad Sci. 2004;1015:202–13.
Taegtmeyer H, Lam T, Davogustto G. Cardiac metabolism in perspective. Compr Physiol. 2016;6:1675–99.
Davogustto G, Taegtmeyer H. The changing landscape of cardiac metabolism. J Mol Cell Cardiol. 2015;84:129–32.
Taegtmeyer H, Hems R, Krebs HA. Utilization of energy-providing substrates in the isolated working rat heart. Biochem J. 1980;186:701–11.
Osterholt M, Sen S, Dilsizian V, Taegtmeyer H. Targeted metabolic imaging to improve the management of heart disease. JACC Cardiovasc Imaging. 2012;5:214–26.
Depre C, Young ME, Ying J, Ahuja HS, Han Q, Garza N, et al. Streptozotocin-induced changes in cardiac gene expression in the absence of severe contractile dysfunction. J Mol Cell Cardiol. 2000;32:985–96.
Goodwin GW, Taylor CS, Taegtmeyer H. Regulation of energy metabolism of the heart during acute increase in heart work. J Biol Chem. 1998;273:29530–9.
Nguyen VT, Mossberg KA, Tewson TJ, Wong WH, Rowe RW, Coleman GM, Taegtmeyer H. Temporal analysis of myocardial glucose metabolism by 2-[18F]fluoro-2-deoxy-D-glucose. Am J Phys. 1990;259:H1022–31.
Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 2004;18:1692–700.
Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: part I: general concepts. Circulation. 2002;105:1727–33.
Depre C, Shipley GL, Chen W, Han Q, Doenst T, Moore ML, et al. Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Nat Med. 1998;4:1269–75.
Dewald O, Sharma S, Adrogue J, Salazar R, Duerr GD, Crapo JD, et al. Downregulation of peroxisome proliferator-activated receptor-alpha gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species and prevents lipotoxicity. Circulation. 2005;112:407–15.
Feinendegen LE. Myocardial imaging of lipid metabolism with labeled fatty acids. In: Dilsizian V, editor. Myocardial viability: a clinical and scientific treatise. Armonk: Futura; 2000. p. 349–89.
Messina SA, Aras O, Dilsizian V. Delayed recovery of fatty acid metabolism after transient myocardial ischemia: a potential imaging target for “ischemic memory”. Curr Cardiol Rep. 2007;9:159–65.
Gropler RJ, Siegel BA, Sampathkumaran K, Pérez JE, Sobel BE, Bergmann SR, Geltman EM. Dependence of recovery of contractile function on maintenance of oxidative metabolism after myocardial infarction. J Am Coll Cardiol. 1992;19:989–97.
Gropler RJ, Geltman EM, Sampathkumaran K, Pérez JE, Moerlein SM, Sobel BE, et al. Functional recovery after coronary revascularization for chronic coronary artery disease is dependent on maintenance of oxidative metabolism. J Am Coll Cardiol. 1992;20:569–77.
Schelbert HR. Principles of positron emission tomography. In: Skorton DJ, Schelbert HR, Wolf GL, Brundage BH, editors. Marcus cardiac imaging: a companion to Braunwald’s heart disease. 2nd ed. Philadelphia: WB Saunders; 1996. p. 1063–92.
Dilsizian V, Bacharach SL, Beanlands SR, Bergmann SR, Delbeke D, Fischman AJ, et al. ASNC imaging guidelines for nuclear cardiology procedures: PET myocardial perfusion and metabolism clinical imaging. J Nucl Cardiol. 2009;16:651. https://doi.org/10.1007/s12350-009-9094-9.
Dilsizian V. Perspectives on the study of human myocardium: viability. In: Dilsizian V, editor. Myocardial viability: a clinical and scientific treatise. Armonk: Futura; 2000. p. 3–22.
Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, Schelbert H. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med. 1986;314:884–8.
Dilsizian V, Arrighi JA. Myocardial viability in chronic coronary artery disease: perfusion, metabolism and contractile reserve. In: Gerson MC, editor. Cardiac nuclear medicine. 3rd ed. New York: McGraw-Hill; 1996. p. 143–91.
Eitzman D, Al-aouar Z, Kanter HL, vom Dahl J, Kirsh M, Deeb GM, Schwaiger M. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol. 1992;20:559–65.
Di Carli MF, Davidson M, Little R, Khanna S, Mody FV, Brunken RC, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol. 1994;73:527–33.
Di Carli MF, Asgarzadie F, Schelbert HR, Brunken RC, Laks H, Phelps ME, Maddahi J. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation. 1995;92:3436–44.
Haas F, Haehnel CJ, Picker W, Nekolla S, Martinoff S, Meisner H, Schwaiger M. Preoperative positron emission tomography viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol. 1997;30:1693–700.
Srinivasan G, Kitsiou AN, Bacharach SL, Bartlett ML, Miller-Davis C, Dilsizian V. 18F-fluorodeoxyglucose single photon emission computed tomography: can it replace PET and thallium SPECT for the assessment of myocardial viability? Circulation. 1998;97:843–50.
Dilsizian V. FDG uptake as a surrogate marker for antecedent ischemia. J Nucl Med. 2008;49:1909–11.
Camici P, Araujo LI, Spinks T, Lammertsma AA, Kaski JC, Shea MJ, et al. Increased uptake of 18F-fluorodeoxyglucose in postischemic myocardium of patients with exercise-induced angina. Circulation. 1986;74:81–8.
He ZX, Shi RF, Wu YJ, Tian YQ, Liu XJ, Wang SW, et al. Direct imaging of exercise-induced myocardial ischemia with fluorine-18-labeled deoxyglucose and Tc-99m-sestamibi in coronary artery disease. Circulation. 2003;108:1208–13.
Dou KF, Yang MF, Yang YJ, Jain D, He ZX. Myocardial 18F-FDG uptake after exercise-induced myocardial ischemia in patients with coronary artery disease. J Nucl Med. 2008;49:1986–91.
Taegtmeyer H, Dilsizian V. Imaging myocardial metabolism and ischemic memory. Nat Clin Pract Cardiovasc Med. 2008;5:S42–8.
Dilsizian V, Bateman TM, Bergmann SR, Des Prez R, Magram MY, Goodbody AE, et al. Metabolic imaging with beta-methyl-para-[123I]-iodophenyl-pentadecanoic acid (BMIPP) identifies ischemic memory following demand ischemia. Circulation. 2005;112:2169–74.
Krebs H. The Pasteur effect and the relation between respiration and fermentation. Essays Biochem. 1972;8:1–34.
Di Carli MF, Prcevski P, Singh TP, Janisse J, Ager J, Muzik O, Vander HR. Myocardial blood flow, function, and metabolism in repetitive stunning. J Nucl Med. 2000;41:1227–34.
Dickfeld T, Lei P, Dilsizian V, Jeudy J, Dong J, Voudouris A, et al. Integration of three-dimensional scar maps for ventricular tachycardia ablation with positron emission tomography-computed tomography. JACC Cardiovasc Imaging. 2008;1:73–82.
United States Renal Data System. 2018 USRDS annual data report: Epidemiology of kidney disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2018.
Tyralla K, Amann K. Morphology of the heart and arteries in renal failure. Kidney Int. 2003;63:S80–3.
Nishimura M, Tsukamoto K, Hasebe N, Tamaki N, Kikuchi K, Ono T. Prediction of cardiac death in hemodialysis patients by myocardial fatty acid imaging. J Am Coll Cardiol. 2008;51:139–45.
Lodge MA. Evidence for inverse relationship between myocardial glucose utilization with PET and severity of renal dysfunction [abstract]. J Nucl Med. 2007;48(Suppl 2):108P.
Nishimura M, Hashimoto T, Kobayashi H, Fukuda T, Okino K, Yamamoto N, et al. Myocardial scintigraphy using a fatty acid analogue detects coronary artery disease in hemodialysis patients. Kidney Int. 2004;66:811–9.
Dilsizian V, Fink J. Deleterious effect of altered myocardial fatty acid metabolism in kidney disease. J Am Coll Cardiol. 2008;51:146–8.
Fink JC, Lodge MA, Smith MF, Hinduja A, Brown J, Dinits-Pensy MY, Dilsizian V. Pre-clinical myocardial metabolic alterations in chronic kidney disease. Cardiology. 2010;116:160–7.
Hofmann M, Wollert KC, Meyer GP, Menke A, Arseniev L, Hertenstein B, et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation. 2005;111:2198–202.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Taegtmeyer, H., Dilsizian, V. (2021). Imaging Cardiac Metabolism. In: Dilsizian, V., Narula, J. (eds) Atlas of Nuclear Cardiology. Springer, Cham. https://doi.org/10.1007/978-3-030-49885-6_9
Download citation
DOI: https://doi.org/10.1007/978-3-030-49885-6_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-49884-9
Online ISBN: 978-3-030-49885-6
eBook Packages: MedicineMedicine (R0)